BeiGene Revenue and Competitors
Estimated Revenue & Valuation
- BeiGene's estimated annual revenue is currently $1.1B per year.
- BeiGene received $800.0M in venture funding in January 2018.
- BeiGene's estimated revenue per employee is $304,861
- BeiGene's total funding is $6.8B.
- BeiGene's current valuation is $25.4B. (January 2022)
- BeiGene has 3477 Employees.
- BeiGene grew their employee count by 32% last year.
BeiGene Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is BeiGene?
BeiGene, Ltd. (NASDAQ: BGNE) is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States (Cambridge, MA; Fort Lee, NJ; Emeryville, CA & San Mateo, CA), Switzerland and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients. For more information, see www.beigene.com.keywords:Biotechnology,Healthcare
Number of Employees
Employee Growth %
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment...
Both trade on the Hong Kong Stock Exchange and BeiGene is also listed on Shanghai's STAR market, becoming the first biotech from China to be...
On Friday, BeiGene scored an approval in China for tislelizumab as a treatment for second-line patients with locally advanced or metastatic esophageal...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient was dosed in the global Phase 3 AdvanTIG-302 trial of BeiGene’s investigational anti-TIGIT antibody ociperlim ...
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--Mar 2, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA ® (zanubrutinib) has been approved by Health Can ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|